Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma
- PMID: 31638211
- PMCID: PMC6831203
- DOI: 10.3892/ijo.2019.4902
Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma
Abstract
Osteosarcoma (OS) is the most common primary bone malignancy, mainly affecting children and adolescents. Currently, surgical resection combined with adjuvant chemotherapy has been standardized for OS treatment. Despite great advances in chemotherapy for OS, its clinical prognosis remains far from satisfactory; this is due to chemoresistance, which has become a major obstacle to improving OS treatment. Autophagy, a catabolic process through which cells eliminate and recycle their own damaged proteins and organelles to provide energy, can be activated by chemotherapeutic drugs. Accumulating evidence has indicated that autophagy plays the dual role in the regulation of OS chemoresistance by either promoting drug resistance or increasing drug sensitivity. The aim of the present review was to demonstrate thatautophagy has both a cytoprotective and an autophagic cell death function in OS chemoresistance. In addition, methods to detect autophagy, autophagy inducers and inhibitors, as well as autophagy‑mediated metastasis, immunotherapy and clinical prognosis are also discussed.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831203/bin/IJO-55-06-1213-g00.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831203/bin/IJO-55-06-1213-g01.gif)
Similar articles
-
Autophagy and its role in osteosarcoma.Cancer Med. 2023 Mar;12(5):5676-5687. doi: 10.1002/cam4.5407. Epub 2023 Feb 15. Cancer Med. 2023. PMID: 36789748 Free PMC article. Review.
-
CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.Int J Oncol. 2021 Jul;59(1):49. doi: 10.3892/ijo.2021.5229. Epub 2021 Jun 3. Int J Oncol. 2021. PMID: 34080667 Free PMC article.
-
Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.Cancer Treat Res Commun. 2021;27:100324. doi: 10.1016/j.ctarc.2021.100324. Epub 2021 Jan 27. Cancer Treat Res Commun. 2021. PMID: 33517237 Review.
-
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes.Cancer Immunol Immunother. 2020 May;69(5):745-758. doi: 10.1007/s00262-020-02508-9. Epub 2020 Feb 11. Cancer Immunol Immunother. 2020. PMID: 32047957 Free PMC article.
-
Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.Oncotarget. 2017 May 9;8(19):31465-31477. doi: 10.18632/oncotarget.16356. Oncotarget. 2017. PMID: 28415557 Free PMC article.
Cited by
-
Nanotherapeutics targeting autophagy regulation for improved cancer therapy.Acta Pharm Sin B. 2024 Jun;14(6):2447-2474. doi: 10.1016/j.apsb.2024.03.019. Epub 2024 Mar 18. Acta Pharm Sin B. 2024. PMID: 38828133 Free PMC article. Review.
-
Autophagy Modulation as a Potential Therapeutic Strategy in Osteosarcoma: Current Insights and Future Perspectives.Int J Mol Sci. 2023 Sep 7;24(18):13827. doi: 10.3390/ijms241813827. Int J Mol Sci. 2023. PMID: 37762129 Free PMC article. Review.
-
VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcoma.Cancer Biol Ther. 2023 Dec 31;24(1):2230641. doi: 10.1080/15384047.2023.2230641. Cancer Biol Ther. 2023. PMID: 37405957 Free PMC article.
-
LncRNA MEG3 promotes chemosensitivity of osteosarcoma by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy.Genes Dis. 2021 Nov 24;10(2):531-541. doi: 10.1016/j.gendis.2021.11.004. eCollection 2023 Mar. Genes Dis. 2021. PMID: 37223512 Free PMC article.
-
Hypoxia-Inducible Factor-2α Signaling in the Skeletal System.JBMR Plus. 2023 Feb 26;7(4):e10733. doi: 10.1002/jbm4.10733. eCollection 2023 Apr. JBMR Plus. 2023. PMID: 37065626 Free PMC article. Review.